Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 30,000 shares of Entellus Medical stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $22.26, for a total transaction of $667,800.00. Following the completion of the transaction, the director now directly owns 514,581 shares in the company, valued at approximately $11,454,573.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Entellus Medical Inc. (NASDAQ:ENTL) opened at 21.65 on Tuesday. Entellus Medical Inc. has a 52 week low of $13.72 and a 52 week high of $22.57. The firm’s market cap is $408.08 million. The stock has a 50 day moving average of $19.97 and a 200 day moving average of $18.14.
Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.08. Entellus Medical had a negative return on equity of 41.83% and a negative net margin of 33.54%. The firm earned $18.73 million during the quarter, compared to the consensus estimate of $18.48 million. During the same quarter in the prior year, the firm posted ($0.15) EPS. The business’s revenue was up 23.3% on a year-over-year basis. Equities analysts forecast that Entellus Medical Inc. will post ($1.23) earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in ENTL. Deimos Asset Management LLC purchased a new position in Entellus Medical during the second quarter worth $183,000. Teachers Advisors Inc. increased its position in Entellus Medical by 21.7% in the second quarter. Teachers Advisors Inc. now owns 10,533 shares of the medical technology company’s stock worth $192,000 after buying an additional 1,876 shares during the period. Renaissance Technologies LLC purchased a new position in Entellus Medical during the first quarter worth $207,000. California State Teachers Retirement System increased its position in Entellus Medical by 36.0% in the second quarter. California State Teachers Retirement System now owns 15,717 shares of the medical technology company’s stock worth $287,000 after buying an additional 4,160 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock worth $312,000 after buying an additional 210 shares during the period. 66.22% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have recently commented on the stock. BTIG Research reissued a “buy” rating on shares of Entellus Medical in a research report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, August 8th. Canaccord Genuity restated a “buy” rating and issued a $23.00 price objective on shares of Entellus Medical in a research note on Friday, August 5th. Deutsche Bank AG assumed coverage on shares of Entellus Medical in a research note on Thursday, October 6th. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Bank of America Corp. restated a “buy” rating on shares of Entellus Medical in a research note on Monday, July 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Entellus Medical currently has an average rating of “Buy” and a consensus target price of $22.75.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.